The RNA-binding protein ESRP1 promotes human colorectal cancer progression by FAGOONEE, SHARMILA et al.
Oncotarget10007www.impactjournals.com/oncotarget
The RNA-binding protein ESRP1 promotes human colorectal 
cancer progression
Sharmila Fagoonee1,2, Gabriele Picco3,9, Francesca Orso2, Arrigo Arrigoni4, Dario 
L. Longo1,2, Marco Forni5, Irene Scarfò6, Adele Cassenti7, Roberto Piva6, Paola 
Cassoni7, Lorenzo Silengo1,2, Emanuela Tolosano2, Silvio Aime2, Daniela Taverna2, 
Pier Paolo Pandolfi2,8, Mara Brancaccio2, Enzo Medico3, Fiorella Altruda1,2
1Institute of Biostructure and Bioimaging, CNR, Department of Molecular Biotechnology and Health Sciences, University of 
Turin, Italy
2Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy
3Candiolo Cancer Institute-IRCCS, University of Turin, Italy
4S.C. Gastroenterologia U, Endoscopia San Giovanni A.S., Azienda Città' della Salute e della Scienza di Torino, Turin, Italy
5EuroClone S.p.A Research Laboratory, Molecular Biotechnology Centre, University of Turin, Italy
6Center for Experimental Research and Medical Studies, University of Turin, Italy
7Department of Medical Sciences, University of Turin, Italy
8Cancer Research Institute, BIDMC, Harvard Medical School, Boston, USA
9present address: Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK
Correspondence to: Sharmila Fagoonee, email: sharmila.fagoonee@unito.it
Fiorella Altruda, email: fiorella.altruda@unito.it
Keywords: ESRP1, RNA binding protein, proto-oncogene, human colorectal cancer
Received: June 08, 2016    Accepted: December 01, 2016    Published: December 28, 2016
ABSTRACT
Epithelial splicing regulatory protein 1 (ESRP1) is an epithelial cell-specific 
RNA binding protein that controls several key cellular processes, like alternative 
splicing and translation. Previous studies have demonstrated a tumor suppressor 
role for this protein. Recently, however, a pro-metastatic function of ESRP1 has been 
reported. We thus aimed at clarifying the role of ESRP1 in Colorectal Cancer (CRC) 
by performing loss- and gain-of-function studies, and evaluating tumorigenesis and 
malignancy with in vitro and in vivo approaches. We found that ESRP1 plays a role 
in anchorage-independent growth of CRC cells. ESRP1-overexpressing cells grown in 
suspension showed enhanced fibroblast growth factor receptor (FGFR1/2) signalling, 
Akt activation, and Snail upregulation. Moreover, ESRP1 promoted the ability of CRC 
cells to generate macrometastases in mice livers. High ESRP1 expression may thus 
stimulate growth of cancer epithelial cells and promote colorectal cancer progression. 
Our findings provide mechanistic insights into a previously unreported, pro-oncogenic 
role for ESRP1 in CRC, and suggest that fine-tuning the level of this RNA-binding 
protein could be relevant in modulating tumor growth in a subset of CRC patients.
INTRODUCTION
Colorectal cancer (CRC) is the third most common 
cancer worldwide [1]. Colorectal carcinogenesis is a 
complex process in which the activation of oncogenes 
and inactivation of tumor suppressor genes affect 
several critical cancer-related pathways [2, 3]. Recent 
advances in the field of CRC have highlighted several 
new key regulators of tumour initiation and progression, 
including short and long regulatory non-coding RNAs 
[4, 5]. Dysregulation in these molecules may alter many 
gene regulatory networks at the transcriptional, post-
transcriptional or epigenetic level leading to cancer cell 
transformation.
RNA-binding proteins (RBPs) are also important for 
the genomic regulatory network within a cell and exert 
an array of functions, ranging from alternative splicing 
to mRNA translation and RNA degradation [6]. Due to 
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their central role in RNA biogenesis, the expression of 
RBPs should be finely tuned in the cell [7]. Importantly, 
in several tissues, like the colon, RBPs are consistently 
and significantly highly expressed with respect to other 
classes of genes such as transcription factors, pointing 
out to the relevance of post-transcriptional regulation in 
maintaining homeostasis in these settings [7]. RBPs are 
emerging as key regulators of several processes in colon 
carcinogenesis. For instance, the RBP Quaking controls 
the differentiation of colon epithelium and acts as a 
suppressor of tumorigenesis [8]. Importantly, alterations 
in RBPs expression or mutation in the binding sites 
of target RNAs may lead to the formation of aberrant 
ribonucleoprotein complexes, thus changing their function 
and contributing to cancer initiation [9]. The RBP Musashi 
RNA-Binding Protein 2, for example, shows elevated 
expression in colorectal adenocarcinomas and promotes 
intestinal transformation [10]. The finding that RBPs can 
act both as oncogene or tumor suppressor, like Hu Antigen 
R, further complicates this issue [11].
Epithelial Splicing Regulatory Protein 1 (ESRP1) 
is an epithelial cell-specific RBP and splicing factor, 
which was first identified as a tumor suppressor in the 
colon adenocarcinoma cell line, LS180, due to its ability 
to bind to the 5’UTR of several cancer-related genes 
and regulate their translation [12]. The ESRP1 gene 
was also found to be the target of biallelic inactivating 
mutations in human colon cancers with microsatellite 
instability [13]. In agreement with the tumor suppressive 
role of ESRP1, several studies have shown that ESRP1 
negatively regulates Epithelial-to-Mesenchymal Transition 
(EMT) in breast and pancreatic cancer, in oral squamous 
cell and non-small cell lung carcinomas [14,15,16,17]. 
Paradoxically, however, a pro-metastatic activity of 
ESRP1 has also been reported. ESRP1 expression in 
4T1 breast cancer cells has been shown to enhance 
their metastatic potential and high ESRP1 expression is 
associated with poor survival of breast cancer patients 
[18]. Moreover, brain-metastatic progression of melanoma 
is positively correlated with the expression of CD44v6 
isoform, a splicing target of ESRP1 [19]. More recently, 
Wang et al. described an association between copy number 
gains at three regions on chromosome 8, including 8q22 
where ESRP1 is located and poor survival of gastric 
cancer patients [20].
In the present study, using both loss- and gain-
of-function approaches, we demonstrate that ESRP1 
plays a role in anchorage-independent growth of CRC 
cells. ESRP1-overexpressing CRC cells, when grown 
in suspension, show enhanced fibroblast growth factor 
receptor (FGFR1/2) signalling, Akt activation, and Snail 
upregulation. Furthermore, ESRP1 promoted the ability 
of CRC cells to generate macrometastases in mice livers. 
High ESRP1 expression may thus stimulate growth of 
cancer epithelial cells in the colon as well as at distant 
sites, and promote colorectal cancer progression.
RESULTS
ESRP1 is overexpressed in a subset of human 
CRC samples
To understand the role of ESRP1 in CRC, we 
examined ESRP1 expression in previously described 
Tissue Microarray (TMA) of primary human colon 
cancer by immunohistochemistry [21]. The intensity of 
ESRP1 expression in 75 out of 80 evaluable CRC sections 
stained was quite heterogeneous. Tumor sections showed 
moderate (nuclear or nuclear/cytoplasmic) (Figure 1A 
i-iv and Supplementary Figure 1A) to high ESRP1 
immunoreactivity (Figure 1A v-vi and Supplementary 
Figure 1A) compared to normal human colon in which 
ESRP1 immunoreactivity was mainly found in the 
nuclei of cells of the mucosa (Figure 1A vii, viii and 
Supplementary Figure 1A). Consistently, analysis of 
cancer genome atlas (TCGA) data from 450 human 
CRC samples revealed that ESRP1 expression was 
extremely heterogeneous, with RNA-Seq by Expectation 
Maximization (RSEM) values ranging from below 200 to 
over 8000. Based on ESRP1 mRNA expression (z-scores), 
16% of the CRC samples had indeed elevated levels 
(z-score >1) and 13% of samples showed below-average 
ESRP1 expression (z-score <-1) (Figure 1B). Moreover, 
classification of ESRP1 expression versus molecular 
subtyping of CRC revealed that ESRP1 expression was 
elevated in some subtypes of tumors (Supplementary 
methods and Supplementary Figure 1B). In particular, 
C1 (Chromosomal Instability (CIN)
ImmuneDown
), C3 (KRAS-
mutant) and C5 (CINWntUp) molecular subtypes of CRC 
showed a mild but statistically significant increase in 
ESRP1 expression compared to the other subtypes 
(Supplementary Figure 1B) [22].
As human CRC cell lines are relevant cancer models 
for studying gene function, we also interrogated our gene 
expression dataset, previously generated using a panel 
of 151 CRC cell lines, for ESRP1 expression [23]. In 
agreement with TCGA data, ESRP1 expression values 
ranged over more than one order of magnitude, with 15% 
of CRC cell lines expressing high levels (z-score >1) and 
14% of cells expressing low levels (z-score <-1) (Figure 
1C). We thus selected 6 CRC cell lines that expressed 
low (z-score < -1), intermediate (-1 ≥ z-score ≤ 1) or high 
(z-score >1) levels of ESRP1 for our in vitro studies, and 
ESRP1 expression was validated both at the RNA and 
protein levels (Figure 1D and E, respectively).
ESRP1 promotes proliferation and 
tumorigenicity of CRC cells in vitro
ESRP1 has been described as a tumor suppressor in 
several types of cancers [14,15]. We thus knocked down 
ESRP1 in HCA24 cells (ESRP1high) to investigate the 
effect of ESRP1 silencing on CRC progression. HCA24 
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Figure 1: ESRP1 expression in CRC patients and cell lines. A. Immunohistochemical analysis of ESRP1expression in human 
CRC sections and normal colonic mucosa: i-vi: tumor (grade I-III), vii-viii: normal colon (scale bar, 100µM). Arrowheads show ESRP1 
positivity. B. Z-score of ESRP1 mRNA expression levels from TCGA RNA-seq data (450 tumor samples), showing tumors with high (red 
dots) and low (blue dots) ESRP1 expression. Z-score between 1 and -1 was considered normal. C. ESRP1 expression in 151 CRC cell lines 
were extracted from GEO and show cell lines with z-score >1 and <-1. D. qRT-PCR analysis of ESRP1 mRNA levels in selected cells lines 
versus normal colon (n=6; t-test of cell lines versus normal colon is shown). E. Representative western blot and densitometric analyses of 
ESRP1 in selected CRC cell lines versus normal colon (3 independent experiments).
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cells were infected with lentivirus prepared with three 
different shRNA sequences (Sh3, Sh4 and Sh5) giving 
efficient knockdown of ESRP1 expression as confirmed 
by analysis of mRNA (Figure 2A) and protein (Figure 
2B) levels. The specificity of the shRNAs was verified 
by analyzing the expression of the alternatively spliced 
isoforms of ESRP1 target genes, ENAH [Enabled 
Homolog (Drosophila)] and FGFR2, and as expected, 
there was an increase in the mesenchymal isoforms 
(ENAH 11-12 and FGFR2 IIIc) upon ESRP1 silencing in 
HCA24 cells (Figure 2C and Supplementary Figure 1C). 
Surprisingly, in HCA24 cells, constitutive knockdown of 
ESRP1 abrogated the growth in suspension (Figure 2D) 
and reduced the anchorage-independent growth versus Scr 
controls (Figure 2E). We performed a rescue experiment 
by substituting 3 bases in three different codons of the 
Sh4 binding site present in the ESRP1 overexpression 
construct. Transfection of the mutant construct in ESRP1-
silenced HCA24 (Sh4) cells rescued the anchorage-
independent growth ability as well as ESRP1-regulated 
gene expression of these cells to levels comparable to 
Scr controls (Figure 2F and Supplementary Figure 2A, 
respectively). ESRP1 silencing in another transformed 
CRC cell line, HDC142 (ESRP1intermediate) also abolished 
their colony-forming capacity in soft agar (Supplementary 
Figure 2B). These data indicate that constitutive silencing 
of ESRP1 expression reduced anchorage-independent 
CRC cell growth.
To investigate a potential oncogenic role for 
ESRP1 in CRC, we chose Caco-2 cells, a normal-
like colon cell line (ESRP1intermediate), to perform both 
loss- and gain-of-function experiments. Upon ESRP1-
silencing, proliferation in suspension (Supplementary 
Figure 3) or anchorage-independent growth (not shown) 
of Caco-2cells, which usually do not grow in anchorage-
independency, did not change versus Scr controls. We 
next stably overexpressed ESRP1 in the non-transformed 
Caco-2 cells, and overexpression was confirmed both 
at mRNA (Figure 3A) and protein (Figure 3B) levels. 
Analysis of ESRP1-regulated genes, ENAH and FGFR2, 
showed that there was a statistically significant increase 
in the expression of the epithelial isoform of the former 
(ENAH 11-11a-12), but a slight decrease in the FGFR2 
IIIb/ IIIc (epithelial/mesenchymal) ratio (Figure 3C). 
Remarkably, elevated ESRP1 expression promoted the 
proliferation of Caco-2 cells in suspension (Figure 3D) 
and colony formation in soft agar assay after 60 days of 
culture compared to the Empty controls, thus indicating 
a role for ESRP1 in the anchorage-independent growth 
of Caco-2 cells (Figure 3E). Moreover, we restored 
ESRP1 expression (Figure 4A and 4B) in an ESRP1-
null COLO320DM cells (ESRP1low) presenting poorly-
differentiated features and growth in semi-suspension. 
Analysis of ESRP1-regulated genes showed that there 
was a statistically significant decrease in the expression of 
the epithelial isoform of ENAH, and a significant increase 
in the FGFR2 IIIb/ IIIc (epithelial/mesenchymal) ratio 
(Figure 4C). Again, ESRP1-expressing COLO320DM 
cells showed a slight but statistically significant increase 
in proliferation in suspension cultures compared to Empty 
controls (Figure 4D) confirming the data obtained in 
ESRP1-overexpressing Caco-2 cells. Overall, in vitro 
analysis in 4 different colon cancer cell lines indicated 
a pro-oncogenic role of ESRP1 in CRC, in particular 
in sustaining anchorage-independent growth and 
transformation.
ESRP1 enhances primary tumor growth in vivo
We further confirmed the in vitro results by 
performing xenograft assays with ESRP1-silenced and 
-overexpressing Caco-2 cells. Caco-2 cells were injected 
subcutaneously in NOD/SCID/gamma-null (NSG) mice 
which were monitored weekly. Visible tumors formed 
45 days after cell injection and grew very fast thereafter, 
and all tumors were dissected 60 days after cell injection. 
The results showed that while ESRP1-silenced tumors 
were significantly smaller compared to Scr control tumors 
(Figures 5A to 5E), ESRP1-overexpressing Caco-2 cells 
generated significantly larger tumors compared to Empty 
controls (Figures 5F to 5J). Altogether, these findings 
strongly support an important role for ESRP1 in promoting 
tumor growth.
ESRP1–driven transformation is PI3K/Akt-
dependent
As Akt is a potent survival factor in colorectal 
carcinogenesis, we next addressed whether the PI3K/Akt 
signaling pathway is involved in the phenotype observed 
in ESRP1-overexpressing Caco-2 cells [24]. Interestingly, 
when ESRP1-overexpressing Caco-2 cells were grown 
in suspension for 24 h, cell aggregates formed, and Akt 
was significantly more phosphorylated at Ser473, reflecting 
a higher Akt activity, compared to basal conditions and 
Empty controls. This increase remained constant in the 
suspension cultures up to 72 h (the last analyzed time 
point, Figure 6A). Treatment of ESRP1-overexpressing 
Caco-2 cells with ZSTK474, a selective PI3K inhibitor, 
significantly reduced colony formation in soft agar (Figure 
6B) and rescued the enhanced growth in suspension to 
levels comparable to Empty controls (Figure 6C), showing 
that the PI3K/Akt pathway was implicated in ESRP1-
driven Caco-2 cell survival and transformation [25].
The oncogenic effects of ESRP1 on CRC cells are 
dependent on FGFR activation
As the receptor tyrosine kinase (RTK) Fibroblast 
Growth Factor Receptor (FGFR) 2 is a known splicing 
target of ESRP1 and is highly expressed in some CRC 
cell lines, we investigated whether the FGFR pathway 
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Figure 2: ESRP1-silencing reduces tumorigenicity of CRC cells. A. Representative qRT-PCR and B. western blotting analyses 
of ESRP1 expression in ESRP1-silenced (Sh3, Sh4 and Sh5) and control (Scr) HCA24 cells. C. qRT-PCR analysis of ESRP1-regulated 
gene expression. D. MTT proliferation assays of ESRP1-silenced versus Scr control HCA24 cells grown in suspension (n=8, 2 independent 
experiments). E. Soft agar assay with ESRP1-silenced and control HCA24 cells (n=3, 2 independent experiments) and Image J software 
quantification of pixels/well (n=6). F. MTT proliferation assays of ESRP1-silenced (Sh4) versus Scr control and Sh4 rescued HCA24 cells 
grown in suspension (n=6, 2 independent experiments, *a is t-test comparing Scr vs Sh4 resc, **, *** is t-test comparing Sh4 vs Scr and 
Sh4 vs Sh4 resc).
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was involved in the activation of Akt in the ESRP1-
overexpressing cells [23,26]. In Caco-2 cells grown in 
suspension, we did not find any significant difference in 
the FGFR2IIIb/IIIc ratio between ESRP1-overexpressing 
cells and Empty controls up to 72 h (Supplementary Figure 
4A). However, further analysis of the FGFR activation 
(phosphorylation at Tyr653 and Tyr654) in these cells showed 
that FGFR was more phosphorylated at 24 h in suspension 
in ESRP1-overexpressing Caco-2 cells compared to 
Empty controls (Supplementary Figure 4B). Treatment 
of ESRP1-overexpressing Caco-2 cells (grown for 24 h 
in suspension) with AZD-4547, a FGFR1/2 inhibitor, 
resulted in significantly reduced FGFR phosphorylation 
as well as in reduced AKTSer473 phosphorylation at 1 
Figure 3: ESRP1 overexpression promotes proliferation and transformation of Caco-2 cells. A. qRT-PCR and B. western 
blotting analyses of ESRP1 expression in Caco-2 cells (Empty controls versus ESRP1-overexpressing (ESRP1)). C. qRT-PCR analysis 
of ESRP1-regulated gene expression. D. MTT proliferation assays of ESRP1-overexpressing Caco-2 cells versus Empty controls grown 
in suspension (n=8, 2 independent experiments). E. Soft agar assay performed with ESRP1-overexpressing and control Caco-2 cells (6 
independent experiments), Image J software quantification of pixels/well and colony counts.
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hr post-treatment showing that the FGFR pathway 
was activated in these cells (Figure 6D). Moreover, 
the FGFR substrate 2 and adaptor protein, FRS2, also 
showed enhanced expression as well as phosphorylation 
in ESRP1-overexpressing Caco-2 cells with respect to 
Empty controls following growth in suspension for 24 
h (Supplementary Figure 4B). Knockdown of FGFR2 
expression in ESRP1-overexpressing Caco-2 cells reduced 
the size of the soft agar colonies showing that FGFR2 
participated in anchorage-independent tumor growth 
(Supplementary Figure 4C).
Ligands causing FGFR activation are usually 
produced by stromal cells, but tumor cells can also 
establish an autocrine loop to aberrantly activate the 
FGFR pathway. We thus analyzed the expression of 
FGFR ligands specific for FGFR2IIIb (FGF7 and FGF10) 
and FGFR2IIIc (FGF2 and FGF18) isoforms. While 
FGF10 and FGF18 were not expressed by Caco-2 cells, 
FGF7 mRNA expression was significantly increased in 
ESRP1-overexpressing cells in suspension compared to 
Empty controls (Figure 6E). FGF2 (which activates both 
FGFR1 and FGFR2IIIc) expression was higher in ESRP1-
overexpressing Caco-2 cells under basal conditions as 
well as in suspension cultures (Supplementary Figure 4) 
compared to Empty controls. Further analysis at protein 
level showed that secreted FGF7, which binds specifically 
the ESRP1-promoted FGFR2IIIb isoform, was detectable 
in the culture supernatant of ESRP1-overexpressing Caco-
2 cells following growth in suspension for 48 h (Figure 
6F), suggesting an autocrine activation of FGFR2IIIb in 
these cells. In the ESRP1-overexpressing cells, FGF7 
mRNA (half-life: 140 mins) showed enhanced stability 
compared to other mRNAs analyzed (Supplementary 
Figure 5) [27]. However, ESRP1did not bind FGF7 mRNA 
as revealed by RNA-IP experiment, suggesting an indirect 
control of its stability (Figure 7D and Supplementary 
Figure 4: Overexpression of ESRP1 in COLO320DM cells. A. qRT-PCR and B. western blotting analyses of ESRP1 expression 
in ESRP1-overexpressing and control COLO320DM cells (n=2, 2 independent experiments). C. qRT-PCR analysis of ESRP1-regulated 
gene expression. D. MTT proliferation assays of ESRP1-overexpressing COLO320DM cells versus Empty controls grown in suspension 
(n=8, 2 independent experiments).
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Figure 5B). Importantly, treatment of Empty control 
Caco-2 cells with FGF7 resulted in colony formation in 
soft agar assay compared to non-treated cells (Figure 6G). 
FGF7 treatment also significantly enhanced the growth 
of ESRP1-overexpressing Caco-2 cells in soft agar as 
evidenced by the increase in number of colonies with 
respect to non-treated cells. These data show that ESRP1 
overexpression caused increased FGFR ligand production 
and receptor activation when Caco-2 cells were grown in 
suspension.
ESRP1 overexpression enhances formation of 
macrometastases from CRC cells
The PI3K/Akt pathway, through the phosphorylation 
of numerous substrates, is associated with processes 
underlying EMT and metastasis of cancer cells [28]. In 
particular, phosphorylation of one of these substrates, 
GSK3β, by Akt at Ser9 inhibits its activity and leads to 
an enhanced stabilization of the zinc-finger protein, Snail 
[29]. We thus analyzed the expression of Snail in our 
system. We found that Snail was expressed in ESRP1-
overexpressing Caco-2 cells grown in suspension in 
serum-free media for 48 h compared to Empty controls 
(Figure 7A). We also observed a significant increase in 
Snail mRNA level in ESRP1-overexpressing cells in 
suspension cultures as from 48 h (Figure 7B). Caco-
2 cells transfected with a Snail-luciferase construct 
and subsequently grown for 72 h in suspension were 
analysed in a dual reporter assay. The results show 
that Snail protein activity was significantly enhanced 
in ESRP1-overexpressing cells compared to Emtpy 
Figure 5: ESRP1 overexpression promotes tumor growth in NSG mice in vivo. A. qRT-PCR and B. western blotting analyses 
of ESRP1 expression in ESRP1-silenced Caco-2 cells. C. Representative tumors are shown. Tumor D. weight and E. volume are shown in 
the graphs (n=8, 2 independent experiments). F. qRT-PCR and G. western blotting analyses of ESRP1 expression in ESRP1-overexpressing 
and control Caco-2 cells. H. Representative tumors are shown. I. Tumor weight and J. volume are shown in the graphs (n=8, 2 independent 
experiments).
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Figure 6: Pathways involved in ESRP1-driven CRC cell transformation. A. Western blot analysis of phospho-AKT 
(pAKTser473) expression in ESRP1-overexpressing Caco-2 cells versus Empty controls following growth in suspension for 72 h. Images 
are representative of 3 independent experiments. B. Soft agar assay and Image J software quantification of pixels/well (n=6) of ESRP1-
overexpressing Caco-2 cells untreated or treated with PI3K inhibitor ZSTK474 (inh) (n=3, 2 independent experiments). C. MTT assay 
proliferation of ESRP1-overexpressing Caco-2 cells following PI3K inhibition versus Empty controls. D. Western blot and densitometric 
analyses of pAKTser473, total AKT, phospho-FGFRTyr6537654, total FGFR1 and FGFR2 expression in ESRP1-overexpressing Caco-2 cells 
grown in suspension untreated and treated for 1h with FGFR inhibitor (3 independent experiments). E. qRT-PCR analysis of FGF7 mRNA 
expression in ESRP1-overexpressing and control Caco-2 cells grown in suspension for 72 h (n=6, 3 independent experiments). F. ELISA 
for human FGF7 was performed in serum-free culture supernatant of ESRP1-overexpressing and control Caco-2 cells grown in suspension 
for 72 h (3 independent experiments). G. Soft agar assay colony counts of Empty and ESRP1-overexpressing Caco-2 cells, treated with 
FGF7 versus non-treated controls (n=3, 2 independent experiments).
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Figure 7: ESRP1 overexpression induces Snail expression and enhances metastasis formation. A. Western blot, 
densitometric and B. qRT-PCR analyses of Snail expression in ESRP1-overexpressing and control Caco-2 cells grown in suspension for 
72 h (3 independent experiments). C. Snail-Luciferase dual reporter assay performed in Empty and ESRP1-overexpressing Caco-2 cells 
grown in serum-free media and in suspension for 72 h. Fold change with respect to basal-LUC is shown (n=4, 2 independent experiments). 
D. RNA-IP performed on ESRP1-overexpressing Caco-2 cells and qRT-PCR analysis of ESRP1-bound transcripts (n=4, 2 independent 
experiments). E. qRT-PCR analysis of Snail mRNA stability following actinomycin D treatment (2 independent experiments). F. Western 
blot analysis of representative CRC tumor samples, classified according to grading (N: Normal, G1: Grade I, G2: Grade II, G3: Grade III).
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controls and with respect to adherent cells (Figure 7C 
and Supplementary Figure 8, respectively). Interestingly, 
RNA-IP analysis revealed that ESRP1 was able to bind 
Snail mRNA (Figure 7D) without affecting its stability 
(Figure 7E). These data suggest that ESRP1 could regulate 
Snail transcription and/or translation, hence potentiating 
the effect of Akt activation on Snail expression in the 
ESRP1-overexpressing Caco-2 cells. The expression of 
Twist, another member of the helix-loop-helix and zinc-
finger protein families, did not differ between the two 
conditions both at protein (Figure 7A) and RNA levels 
(not shown). Analysis of human CRC samples, classified 
according to grading, further showed that Snail protein 
was expressed in tumors versus normal samples (Figure 
7F). Importantly, the results show that ESRP1 and Snail 
may be co-expressed in human CRC, as seen in the G2 
sample analysed, hence supporting our data on ESRP1-
overexpression in Caco-2 cells.
We further investigated the effect of ESRP1 
overexpression on the metastatic process in vivo. As 
ESRP1-overexpressing Caco-2 cells did not form 
significant metastasis in vivo (Supplementary Figure 
6), we employed another highly metastatic CRC cell 
line, COLO320DM, for experimental metastasis. Three 
weeks after intravenous cell injection, COLO320DM 
cells formed macrometastases in the liver of NSG mice 
as revealed by MRI analysis. ESRP1-overexpressing 
COLO320DM cells resulted in a significantly larger 
number of macrometastases compared to Empty controls 
(Figure 8).
To gain further mechanistic insights into the 
molecular changes caused by ESRP1 modulation, we 
performed gene expression profiling of Caco-2 cells 
grown as monolayer (ESRP1-overexpression and 
ESRP1-silencing, Figure 9A and Supplementary Figure 
7A, respectively). Selected differentially expressed 
genes (Supplementary Table 3) were validated at mRNA 
level (Supplementary Figure 7C). Gene Set Enrichment 
Analysis (GSEA) of these changes revealed that EMT 
and Myc targets were among the most significantly 
enriched terms in ESRP1-overexpressing cells (Figure 9A) 
compared to control cells. On the other hand, we found 
that the expression of EMT-related genes was reduced in 
ESRP1-silenced Caco-2 cells with respect to Scr controls 
(Supplementary Figure 7B).
To deeply investigate the modulation of EMT 
signature genes after ESPR1 overexpression, we extracted 
expression level of all the transcripts present in EMT gene 
set from our cDNA microarray data performed on Caco-2 
cells under adhesion (basal conditions). According to GSEA 
results, the majority of these genes (63%) were upregulated 
in ESRP1-overexpressing Caco-2 cells (Supplementary 
Table 4). Moreover, 6 of these were also selected in the 
ESRP1 signature and, in particular, PMP22 and VCAN 
transcripts were ranked among the top genes induced by 
ESRP1 overexpression (Supplementary Figure 7C).
We also examined Akt pathway in the RNA 
profile by performing in silico functional analysis (see 
Supplementary methods). GSEA revealed that Akt 
pathway gene set was not significantly enriched in ESRP1-
Figure 8: Effect of ESRP1 overexpression on metastatic potential of CRC cells in vivo. Representative MRI T2w images of 
NSG mice injected with COLO320DM cells showing liver macrometastases (arrowheads). Bar graphs of liver macrometastases, n=9 for 
each group.
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overexpressing Caco-2 cells (FDR q-val = 0.87), while 
IPA upstream analysis showed a weak but significant 
activation of AKT signaling pathway (p = 1.88E-02) 
inferred by the positive modulation of Akt target genes 
in ESRP1-overexpressing Caco-2 cells. Overall, these 
results based on mRNA profile suggest that Akt pathway 
is not markedly upregulated in adherent cells after ESRP1 
overexpression. This is in line with the results obtained 
by Western blot in which we were able to highlight AKT 
phosphorylation only when cells were kept in suspension.
Figure 9: Effects of ESRP1 overexpression on cancer cells. A. Gene expression profiling of ESRP1-overexpressing and control 
adherent Caco-2 cells. The heatmap reports the expression (log2 ratio against average). B. GSEA of the transcription profiles shows 
enrichment in gene signatures in ESRP1-overexpressing Caco-2 cells versus Empty controls. C. The cartoon depicts the potential effects 
of ESRP1 overexpression in CRC cells.
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ESRP1-overexpressing cells showed enhanced 
survival in suspension cultures through Akt activation, 
Snail expression as well as other EMT-linked alterations, 
thus promoting CRC cell growth in anchorage-
independency in vitro and macrometastasis formation 
in vivo.
DISCUSSION
RBPs are part of the largest group of proteins 
that orchestrates the passage of RNA through the RNA 
regulon and may coordinate the expression of diverse 
genes responsible for cell growth and proliferation. Thus, 
aberrant expression of RBPs might alter cell physiology 
and lead to cancer development [9]. As an RBP, ESRP1 
is involved in several cellular processes like alternative 
splicing, regulation of translation and mRNA stability 
[30,31]. ESRP1 is a documented tumor suppressor but our 
analysis on CRC cell lines and TCGA expression datasets 
also revealed cases in which this RBP was overexpressed 
[32]. In an attempt to clarify the role of ESRP1 in CRC 
progression, we modulated the level of this protein in 
four cell lines and found a previously unreported, pro-
tumorigenic function of ESRP1 in CRC. Our data provide 
the first evidence that ESRP1 is required for CRC cell 
anchorage-independent growth in vitro and tumor growth 
in vivo. Regarding the underlying mechanism, we show 
that, when Caco-2 cells are grown in suspension, ESRP1 
indirectly causes an increase in the secretion of FGF7 
and FGF2, leading to FGFR activation and sustained Akt 
phosphorylation. FGFR or PI3K/Akt inhibition reverted 
the pro-oncogenic phenotype observed in Caco-2 cells 
upon ESRP1 overexpression.
In ESRP1-overexpressing Caco-2 cells, FGF7 
and FGF2 production participated to an autocrine 
activation of FGFR (FGFR1 and FGFR2), and addition 
of exogenous FGF7 to Caco-2 cells in anchorage-
independent growth assay induced colony formation in 
Empty controls and increased the number of colonies in 
ESRP1-overexpressing cells. Binding of RNA targets by 
ESRP1 usually results in their translational suppression 
without affecting overall mRNA stability [12,31]. Our 
native RNA-IP of ESRP1-bound transcripts in Caco-
2 cells showed that FGF7 mRNA was not bound by 
ESRP1. Thus, the increased stability of FGF7 and FGF2 
mRNA in these cells was probably enhanced by other 
stimuli or mechanism warranting further studies, for 
example through other regulatory RNAs like miRNAs 
[33]. These ligands, usually secreted by stromal cells 
surrounding the tumor, can also be produced by advanced 
cancer cells [34]. Autocrine signalling by many growth 
factor-receptor combinations is a major stimulus of cell 
transformation and, several studies have shown that the 
creation of a FGF7 autocrine loop provides conditions 
in which subsequent changes can occur culminating in 
malignancy [35]. Moreover, aberrant FGF signalling 
and FGFR activation induce proliferation and survival 
of tumor cells [36,37]. Phosphorylated FGFR can lead to 
the activation of multiple signal transduction pathways, 
involving key adaptor proteins, among which FRS2. 
One of the complexes recruited to phosphorylated FRS2 
includes growth factor receptor-bound 2-associated 
binding protein 1 (GAB1) and PI3K which activates Akt-
dependent survival pathway. Our results showed higher 
expression of FRS2 as well as of phosphorylated FRS2 in 
ESRP1-overexpressing Caco-2 cells in suspension cultures 
versus Empty controls.
In CRC, Akt activation is associated with increased 
proliferation and loss of epithelial differentiation [38]. 
Activated Akt phosphorylates several substrates, like 
GSK3β, that are involved in essential cell processes 
like survival and protein translation [24]. Interestingly, 
Akt, through inhibition of GSK3β, can stabilize Snail 
protein which, apart from its well-documented role as 
inducer of EMT, also participates in cell survival, immune 
regulation and stem cell biology [39]. Akt can act through 
phosphorylation of GSK3β or IKKα/ IKK β/NF-κB 
pathway to promote Snail stability and transcription, 
respectively [40,41]. It has been shown by Wang et al. 
that suppression of Akt can result in a distinct reduction 
of Snail expression at mRNA level, hence supporting 
our data [42]. In accordance, we detected an increased 
level of Snail mRNA in ESRP1-overexpressing cells 
grown in suspension. Moreover, our RNA-IP data show 
that ESRP1 can bind Snail mRNA, but has no effect 
on mRNA stability, suggesting that ESRP1 could be 
regulating the translation of Snail. Of note is the fact that 
during carcinogenesis, Snail mRNA can be also stabilized 
by other RBPs like Human antigen R (HuR) [43]. In 
immortalized human mammary epithelial cells, Reinke 
et al. have shown that Snail can regulate the transcription 
of ESRP1, thus facilitating EMT and tumor progression 
[44]. We obtained similar results in adherent cells using 
Snail-luciferase reporter assay. Our data also show that 
overexpression of ESRP1 led to detectable Snail protein 
expression when cells were grown in suspension without 
serum versus Empty controls. The combined effects of 
Akt and FGFR activation upon ESRP1 overexpression 
may account for the increased Snail gene expression in 
the ESRP1-overexpressing Caco-2 cells, and may be 
responsible for the inactivation of the inhibitory loop 
between ESRP1 and Snail. Furthermore, our data show 
ESRP1 can co-express with Snail in some human CRC 
samples. Snail expression has been found upregulated in 
60–70% of CRC, and is associated not only with poor 
prognosis, but also with shortened relapse-free survival 
[45]. We further analysed whether pAKT, pFGFR 
and Snail were involved in the phenotype observed in 
ESRP1-silenced HCA24 cells grown in suspension but 
found that there were no differences between ESRP1-
silenced cells compared to Scr control (not shown). This 
indicates that different mechanisms were responsible for 
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the behaviour of ESRP1-silenced and-overexpressing 
cells in anchorage-independency.
We also observed a significantly higher number 
of macrometastases in the liver of NSG mice with 
ESRP1-overexpressing COLO320DM cells compared 
to Empty controls. This may be due to the ability of 
ESRP1 to promote tumor growth in vivo. ESRP1-induced 
changes, such as Snail expression, did not affect liver 
colonisation of CRC cells as reflected by similar number 
of micrometastases generated by ESRP1-overexpressing 
and Empty control COLO320DM cells, hence supporting 
the data showing that Snail is dispensable for metastasis, 
as occurs in pancreatic cancer [46]. How ESRP1 can 
promote metastatic cell growth in vivo warrants further 
investigation.
The work of Leontieva et al. showed that ectopic 
expression of ESRP1 (RBM35A) in ESRP1-null LS180 
colon carcinoma cells inhibited anchorage-independent 
growth in vitro and suppressed tumorigenic potential 
in vivo [12]. This apparent contrast could be due to the 
fact that the authors used a Tet-off regulated system 
to obtain physiological level of ESRP1 in LS180 
cells compared to our constitutive overexpression 
of ESRP1. During the revision of our work, a paper 
was published in which the expression of ESRP1 and 
ESRP2 as well as ESRPs-mediated alternative splicing 
patterns in CRC were analysed [47]. The authors 
showed that CRC cells with reduced expression of 
ESRPs showed splicing patterns associated with EMT. 
Especially, reduced ESRP1 expression switches FGFR2 
expression to more mesenchymal splice variants with a 
strong potential of disease progression, and showed a 
correlation between ESRPs expression and a favorable 
outcome in CRC. These are not surprising considering 
the evidences showing that a number of genes, often 
coding for multifunctional proteins like ESRP1, show 
oncogenic activities both when over- or under-expressed, 
highlighting a need for fine tuning of their expression 
levels in normal cells [48].
In conclusion, our data show, for the first time, 
that aberrantly high ESRP1 expression can drive tumor 
progression in CRC. RBP activity, in contrast with 
transcription factors, is restricted to the repertoire of 
transcripts expressed in a given cell type [10]. Thus, 
RBPs may serve as a hub of signal integration by 
acting on mRNAs available for binding in a given cell 
type hence performing cell-type-specific function. The 
autocrine activation of FGFR2, enhanced Akt activation, 
increased Snail expression in CRC cells constitutively 
overexpressing ESRP1, as depicted in Figure 9C, may 
instigate cell protection mechanisms causing cell survival 
in suspension cultures. Maintaining a finely tuned 
expression of ESRP1 is important in epithelial cells as 
elevated ESRP1 levels may post-transcriptionally alter 
expression of genes involved in pathways that synergize 
to drive cancer, as happens in a subset of CRC.
MATERIALS AND METHODS
CRC cell lines
The CRC cell lines used in this study were tested 
and authenticated, and characterized by genetic and 
transcriptional profiling as we previously reported in 2015 
[23]. Culture media used are described in Supplementary 
methods. Cells were treated with 10-9 M FGF7 (Peprotech)
[49], 5µM of the FGFR inhibitor, AZD4547 (Selleck 
Chemicals) or 1µM of the PI3K inhibitor, ZST K474 (kind 
gift from E. Ciraolo).
Stable ESRP1 knockdown and overexpression in 
CRC cell lines
Five shRNA (TRCN0000240872- 
TRCN0000240875 and TRCN0000240878, 
Openbiosystems) were analyzed for efficient knockdown 
of Esrp1 in HCA24 cells using Lipofectamine 2000 
(Invitrogen) and according to manufacturer’s instructions. 
Lentivirus was produced in 293FT cells as previously 
described [31]. For overexpression of ESRP1 and 
lentivirus production, human ESRP1 ORF (HORFEOME 
v8.1, OpenBiosystems) was cloned into pLX304 by 
gateway recombination. After infection, cells were 
selected using puromycin (pLKO.1) or blasticidin 
(pLX304) prior to performing experiments.
Luciferase reporter gene assays
Basic-LUC or Snail-LUC (Snail_pGL2 was 
from Paul Wade (Addgene plasmid # 31694)) and 
Renilla plasmids were transfected into Caco-2 cells 
using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer's guidelines [50]. After transfection, cells 
were grown in suspension in serum-free media for 72h. 
Luciferase reporter gene assays were conducted using the 
Luciferase Assay System (Promega) and its corresponding 
protocol.
RNA extraction, PCR and real-time PCR
RNA was extracted using the PureLink RNA kit 
(Ambion) and cDNA prepared using the High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). 
Target gene expression was analyzed by Real-time PCR 
(qRT-PCR) (Supplementary Table 1) and normalized to 
endogenous 18s expression as previously described [31]. 
Primers used for PCR are listed in Supplementary Table 1.
RNA stability assay
Actinomycin D (Sigma) treatment (10µg/ml) was 
performed for the indicated time points as previously 
reported [31] and RNA was extracted and analyzed by 
qRT-PCR as described above.
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Human colorectal cancer tumor samples and 
immunohistochemistry
For immunohistochemical evaluation of ESRP1, 
five TMA with 1mm cores from colon cancer (80 cases), 
prepared as previously described, were obtained from the 
Dept. of Surgical Pathology, University of Turin [21]. After 
antigen retrieval, sections were stained with anti-ESRP1 
antibody (Sigma) and revealed with biotinylated anti-rabbit 
antibody and the ABC complex (DAKO) followed by 
exposure to 3, 3’-Diaminobenzidine (DAB, Roche).
Colorectal cancer expression datasets
Gene expression data from the 151 CRC cell lines 
were extracted from the Gene Expression Omnibus (GEO, 
accession: GSE59857), normalized and preprocessed 
(expression filtering, removal of redundant probes, log2 
transformation) as previously described [23]. ESRP1 
expression was analyzed in CRC TCGA samples, using 
our previously assembled 450-sample TCGA mRNA 
dataset, as described elsewhere [32].
Gene expression profiling by cDNA microarray 
analysis
For gene expression profiling, RNA was extracted 
using miRNeasy Mini Kit (Qiagen), according to the 
manufacturer’s protocol. RNA quantification, quality 
assessment, cRNA synthesis, hybridization and data 
processing as well as GSEA analysis are described in 
Supplementary methods. ESRP1-overexpressed and 
ESRP1-silenced Caco-2 cells were compared to Empty 
and Scr controls, respectively, by applying a double filter 
based on t-test (P <0.01) and > 1.5 fold-change (absolute 
log2 ratio).
Proliferation assay
Cells (2x103/ well) were cultured in 96-well plates in 
monolayer or suspension (ultra-low attachment, Corning) 
for the indicated time points and performed as previously 
described [31].
Soft agar assay
The soft agar assay was performed as described 
elsewhere [51]. Briefly, 2x105 Caco-2 cells and 1x104 
HCA24, COLO320DM, COGA8, HDC142 cells o 2.4x104 
Snu-C1 cells were plated in the upper layer and stained 2 
months or 3-4 weeks later, respectively, with p-nitroblue 
tetrazolium (NBT, Sigma) for colony visualization and 
counting.
Western blotting
Protein was extracted from cells or from OCT-
embedded normal colon sections as described in 
Supplementary methods and separated by 4-15% 
SDS-PAGE (Biorad). Antibodies used are described 
in Supplementary Table 2. Densitometric analysis was 
performed using the volume analysis tool of ImageLab 
software (Biorad Laboratories Inc).
ELISA
Caco-2 cells (1x106) were grown in 3ml serum-free 
media in 6cm ultra-low attachment and human FGF7 was 
measured using the Human FGF-7 ELISA Kit (Sigma) 
according to the manufacturer’s instructions.
RNA-Immunoprecipitation (RNA-IP)
Cell protein extracts were prepared and used for 
immunoprecipitation with anti-ESRP1 antibody or rabbit 
IgG and for RNA extraction as we previously described [31].
Rescue experiments
For rescue experiments, site directed mutagenesis 
was perfomed on human ESRP1 cDNA in pLX304 using 
QuikChange Lightning Site-directed mutagenesis kit 
(agilent technologies) as per manufacturer's protocol. 
Primers used are described in Supplementary Table 1. 
Reverse transfection with lipofectamine 2000 was used 
for delivery plasmid DNA into cells (Invitrogen).
Primary tumor generation, experimental 
metastasis and ethics statement
All animal procedures were in accordance with Italian 
legislation on animal experimentation, and were approved by 
the Animal Care Committee of the Candiolo Cancer Institute 
and by the Italian Ministry of Health. For primary tumor 
generation, Caco-2 cells (2.5 X 106) were subcutaneously 
injected in NOD-SCID-IL2Rg-null (NSG) mice. When 
tumors reached ~1cm in diameter in control or ESRP1-
modulated condition, mice were sacrificed by carbon dioxide 
inhalation followed by cervical dislocation. For experimental 
metastasis, Caco-2 (2.5 X 106) or COLO320DM (1 X 
105) cells were intravenously injected in NSG mice and 
macrometastases were followed weekly by magnetic 
resonance imaging (MRI) with an Aspect M2 System 
(Aspect Magnet Technologies Ltd., Netanya, Israel) working 
at 1 Tesla by using a dedicated bed for immunocompromised 
mice to maintain sterile conditions. T2-weighted (T2w) 
anatomical images were acquired with a fast spin echo 
sequence (TR 3300 s; TE effective 44 ms; number of slices 
25; slice thickness 1.0 mm; FOV 100 mm; acquisition matrix 
256 × 256; two averages) as previously described [52].
Statistical analyses
Data are expressed as mean ± standard error of mean 
(s.e.m) or standard deviation (s.d). Statistical differences 
were determined by a 2-tailed Student’s t -test (* P <0.05, 
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** P <0.01, *** P <0.001). Error bars in all figures denote 
s.e.m.
ACKNOWLEDGMENTS
Sean Clohessy for scientific discussion, Miriam 
Martini for scientific discussion and critical reading of the 
manuscript, Elisa Ciraolo for providing ZSTK474, Enrico 
Moiso for help with bioinformatics analysis regarding 
subtyping of tumors, Rinaldo Pellicano for helpful 
suggestions and critical reading, Marco Cupo for protein 
extraction from human CRC samples.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
GRANT SUPPORT
to FA: Progetti di ricerca di interesse nazionale 
(PRIN) 2010, Telethon 2014, Prometeo, Advanced Life 
Science in Italy (Alisei)
to EM: Associazione Italiana per la Ricerca 
sul Cancro (AIRC) investigator grants (IG12944), 
Associazione Italiana per la Ricerca sul Cancro (AIRC) 
9970-2010 Special Program Molecular Clinical Oncology 
5x1000, Fondazione Piemontese per la Ricerca sul Cancro 
5x1000 Ministero della Salute 2010 and 2011
to DT: Associazione Italiana per la Ricerca sul 
Cancro (AIRC) 2013 (IG2013-14201), Fondazione Cassa 
di Risparmio Torino CRT (2014.1085)
to MB: Associazione Italiana per la Ricerca sul 
Cancro AIRC 2014 (IG 15880)
REFERENCES
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, 
Rebelo M, Parkin DM, Forman D, Bray F Cancer incidence 
and mortality worldwide: sources, methods and major 
patterns in GLOBOCAN 2012. International journal of 
cancer. 2015; 136: E359-386.
2. Markowitz SD, Bertagnolli MM Molecular origins of 
cancer: Molecular basis of colorectal cancer. The New 
England journal of medicine. 2009; 361: 2449-2460.
3. Wurth L Versatility of RNA-Binding Proteins in Cancer. 
Comparative and functional genomics. 2012; 2012: 178525.
4. Pizzini S, Bisognin A, Mandruzzato S, Biasiolo M, 
Facciolli A, Perilli L, Rossi E, Esposito G, Rugge M, 
Pilati P, Mocellin S, Nitti D, Bortoluzzi S, et al. Impact of 
microRNAs on regulatory networks and pathways in human 
colorectal carcinogenesis and development of metastasis. 
BMC genomics. 2013; 14: 589.
5. Xu MD, Qi P, Du X Long non-coding RNAs in colorectal 
cancer: implications for pathogenesis and clinical 
application. Modern pathology. 2014; 27: 1310-1320.
6. Anant S, Houchen CW, Pawar V, Ramalingam S Role 
of RNA-Binding Proteins in Colorectal Carcinogenesis. 
Current colorectal cancer reports. 2010; 6: 68-73.
7. Kechavarzi B, Janga SC Dissecting the expression 
landscape of RNA-binding proteins in human cancers. 
Genome biology. 2014; 15: R14.
8. Yang G, Fu H, Zhang J, Lu X, Yu F, Jin L, Bai L, Huang B, 
Shen L, Feng Y, Yao L, Lu Z RNA-binding protein quaking, 
a critical regulator of colon epithelial differentiation and a 
suppressor of colon cancer. Gastroenterology. 2010; 138: 
231-240 e231-235.
9. Kim MY, Hur J, Jeong S Emerging roles of RNA and RNA-
binding protein network in cancer cells. BMB reports. 2009; 
42: 125-130.
10. Wang S, Li N, Yousefi M, Nakauka-Ddamba A, Li F, Parada 
K, Rao S, Minuesa G, Katz Y, Gregory BD, Kharas MG, Yu 
Z, Lengner CJ Transformation of the intestinal epithelium 
by the MSI2 RNA-binding protein. Nature communications. 
2015; 6: 6517.
11. Wang J, Guo Y, Chu H, Guan Y, Bi J, Wang B Multiple 
Functions of the RNA-Binding Protein HuR in Cancer 
Progression, Treatment Responses and Prognosis. 
International journal of molecular sciences. 2013; 14: 
10015-10041.
12. Leontieva OV, Ionov Y RNA-binding motif protein 35A is 
a novel tumor suppressor for colorectal cancer. Cell cycle. 
2009; 8: 490-497.
13. Ivanov I, Lo KC, Hawthorn L, Cowell JK, Ionov Y 
Identifying candidate colon cancer tumor suppressor genes 
using inhibition of nonsense-mediated mRNA decay in 
colon cancer cells. Oncogene. 2007; 26: 2873-2884.
14. Shapiro IM, Cheng AW, Flytzanis NC, Balsamo M, 
Condeelis JS, Oktay MH, Burge CB, Gertler FB An EMT-
driven alternative splicing program occurs in human breast 
cancer and modulates cellular phenotype. PLoS genetics. 
2011; 7: e1002218.
15. Ueda J, Matsuda Y, Yamahatsu K, Uchida E, Naito Z, 
Korc M, Ishiwata T Epithelial splicing regulatory protein 
1 is a favorable prognostic factor in pancreatic cancer that 
attenuates pancreatic metastases. Oncogene. 2014; 33: 
4485-4495.
16. Ishii H, Saitoh M, Sakamoto K, Kondo T, Katoh R, Tanaka 
S, Motizuki M, Masuyama K, Miyazawa K Epithelial 
splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) 
suppress cancer cell motility via different mechanisms. The 
Journal of biological chemistry. 2014; 289: 27386-27399.
17. Voena C, Varesio LM, Zhang L, Menotti M, Poggio T, 
Panizza E, Wang Q, Minero VG, Fagoonee S, Compagno 
M, Altruda F, Monti S, Chiarle R. Oncogenic ALK regulates 
EMT in non-small cell lung carcinoma through repression 
of the epithelial splicing regulatory protein 1. Oncotarget. 
2016; 7:33316-33330. doi: 10.18632/oncotarget.8955.
18. Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa 
M, Yoshida GJ, Wada T, Masuko T, Mogushi K, Tanaka H, 
Oncotarget10023www.impactjournals.com/oncotarget
Osawa T, Kanki Y, Minami T, et al. Alternative splicing 
of CD44 mRNA by ESRP1 enhances lung colonization of 
metastatic cancer cell. Nature communications. 2012; 3: 
883.
19. Marzese DM, Liu M, Huynh JL, Hirose H, Donovan 
NC, Huynh KT, Kiyohara E, Chong K, Cheng D, Tanaka 
R, Wang J, Morton DL, Barkhoudarian G, et al. Brain 
metastasis is predetermined in early stages of cutaneous 
melanoma by CD44v6 expression through epigenetic 
regulation of the spliceosome. Pigment cell & melanoma 
research. 2015; 28: 82-93.
20. Wang X, Liu Y, Shao D, Qian Z, Dong Z, Sun Y, Xing X, 
Cheng X, Du H, Hu Y, Li Y, Li L, Dong B, et al. Recurrent 
amplification of MYC and TNFRSF11B in 8q24 is 
associated with poor survival in patients with gastric cancer. 
Gastric cancer. 2015.
21. Calzolari A, Deaglio S, Maldi E, Cassoni P, Malavasi F, 
Testa U TfR2 expression in human colon carcinomas. Blood 
cells, molecules & diseases. 2009; 43: 243-249.
22. Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, 
Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot 
D, Ayadi M, Kirzin S, Chazal M, Flejou JF, et al. Gene 
expression classification of colon cancer into molecular 
subtypes: characterization, validation, and prognostic value. 
PLoS medicine. 2013; 10: e1001453.
23. Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, 
Corti G, Buscarino M, Isella C, Lamba S, Martinoglio 
B, Veronese S, Siena S, Sartore-Bianchi A, et al. The 
molecular landscape of colorectal cancer cell lines unveils 
clinically actionable kinase targets. Nature communications. 
2015; 6: 7002.
24. Urban BC, Collard TJ, Eagle CJ, Southern SL, Greenhough 
A, Hamdollah-Zadeh M, Ghosh A, Poulsom R, Paraskeva 
C, Silver A, Williams AC BCL-3 expression promotes 
colorectal tumorigenesis through activation of AKT 
signalling. Gut. 2015.
25. Dan S, Okamura M, Mukai Y, Yoshimi H, Inoue Y, Hanyu 
A, Sakaue-Sawano A, Imamura T, Miyawaki A, Yamori T 
ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, 
induces G1 arrest of the cell cycle in vivo. European journal 
of cancer. 2012; 48: 936-943.
26. Verstraete M, Debucquoy A, Gonnissen A, Dok R, Isebaert 
S, Devos E, McBride W, Haustermans K In vitro and in 
vivo evaluation of the radiosensitizing effect of a selective 
FGFR inhibitor (JNJ-42756493) for rectal cancer. BMC 
cancer. 2015; 15: 946.
27. Sharova LV, Sharov AA, Nedorezov T, Piao Y, Shaik N, 
Ko MS Database for mRNA half-life of 19 977 genes 
obtained by DNA microarray analysis of pluripotent and 
differentiating mouse embryonic stem cells. DNA research. 
2009; 16: 45-58.
28. Larue L, Bellacosa A Epithelial-mesenchymal transition 
in development and cancer: role of phosphatidylinositol 3' 
kinase/AKT pathways. Oncogene. 2005; 24: 7443-7454.
29. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung 
MC Dual regulation of Snail by GSK-3beta-mediated 
phosphorylation in control of epithelial-mesenchymal 
transition. Nature cell biology. 2004; 6: 931-940.
30. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens 
RP ESRP1 and ESRP2 are epithelial cell-type-specific 
regulators of FGFR2 splicing. Mol Cell. 2009; 33: 591-601.
31. Fagoonee S, Bearzi C, Di Cunto F, Clohessy JG, Rizzi R, 
Reschke M, Tolosano E, Provero P, Pandolfi PP, Silengo 
L, Altruda F The RNA binding protein ESRP1 fine-tunes 
the expression of pluripotency-related factors in mouse 
embryonic stem cells. PloS one. 2013; 8: e72300.
32. Isella C, Terrasi A, Bellomo SE, Petti C, Galatola G, 
Muratore A, Mellano A, Senetta R, Cassenti A, Sonetto 
C, Inghirami G, Trusolino L, Fekete Z, et al. Stromal 
contribution to the colorectal cancer transcriptome. Nature 
genetics. 2015; 47: 312-319.
33. Chedid M, Rubin JS, Csaky KG, Aaronson SA Regulation 
of keratinocyte growth factor gene expression by 
interleukin 1. The Journal of biological chemistry. 1994; 
269: 10753-10757.
34. Shirakihara T, Horiguchi K, Miyazawa K, Ehata S, Shibata 
T, Morita I, Miyazono K, Saitoh M TGF-beta regulates 
isoform switching of FGF receptors and epithelial-
mesenchymal transition. The EMBO journal. 2011; 30: 
783-795.
35. Finch PW, Rubin JS Keratinocyte growth factor expression 
and activity in cancer: implications for use in patients with 
solid tumors. Journal of the National Cancer Institute. 2006; 
98: 812-824.
36. Katoh Y, Katoh M FGFR2-related pathogenesis and 
FGFR2-targeted therapeutics (Review). International 
journal of molecular medicine. 2009; 23: 307-311.
37. Turner N, Grose R Fibroblast growth factor signalling: from 
development to cancer. Nature reviews Cancer. 2010; 10: 
116-129.
38. Suman S, Kurisetty V, Das TP, Vadodkar A, Ramos G, 
Lakshmanaswamy R, Damodaran C Activation of AKT 
signaling promotes epithelial-mesenchymal transition 
and tumor growth in colorectal cancer cells. Molecular 
carcinogenesis. 2014; 53: E151-160.
39. Wu Y, Zhou BP Snail: More than EMT. Cell adhesion & 
migration. 2010; 4: 199-203.
40. Zheng H, Li W, Wang Y, Liu Z, Cai Y, Xie T, Shi M, Wang 
Z, Jiang B Glycogen synthase kinase-3 beta regulates Snail 
and beta-catenin expression during Fas-induced epithelial-
mesenchymal transition in gastrointestinal cancer. European 
journal of cancer. 2013; 49: 2734-2746.
41. Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, van 
Roy F, Dargemont C, de Herreros AG, Bellacosa A, Larue 
L Activation of NF-kappaB by Akt upregulates Snail 
expression and induces epithelium mesenchyme transition. 
Oncogene. 2007; 26: 7445-7456.
Oncotarget10024www.impactjournals.com/oncotarget
42. Wang J, Liu Y, Wang L, Sun X, Wang Y. Clinical prognostic 
significance and pro-metastatic activity of RANK/RANKL 
via the AKT pathway in endometrial cancer. Oncotarget. 
2016; 7: 5564-5575. doi: 10.18632/oncotarget.6795.
43. Dong R, Lu JG, Wang Q, He XL, Chu YK, Ma QJ 
Stabilization of Snail by HuR in the process of hydrogen 
peroxide induced cell migration. Biochemical and 
biophysical research communications. 2007; 356: 318-321.
44. Reinke LM, Xu Y, Cheng C Snail represses the splicing 
regulator epithelial splicing regulatory protein 1 to promote 
epithelial-mesenchymal transition. The Journal of biological 
chemistry. 2012; 287: 36435-36442.
45. Kroepil F, Fluegen G, Vallbohmer D, Baldus SE, Dizdar L, 
Raffel AM, Hafner D, Stoecklein NH, Knoefel WT Snail1 
expression in colorectal cancer and its correlation with 
clinical and pathological parameters. BMC cancer. 2013; 
13: 145.
46. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, 
Sugimoto H, Wu CC, LeBleu VS, Kalluri R Epithelial-to-
mesenchymal transition is dispensable for metastasis but 
induces chemoresistance in pancreatic cancer. Nature. 2015; 
527: 525-530.
47. Deloria AJ, Hoflmayer D, Kienzl P, Lopatecka J, Sampl 
S, Klimpfinger M, Braunschmid T, Bastian F, Lu L, 
Marian B, Stattner S, Holzmann K. Epithelial splicing 
regulatory protein 1 and 2 paralogues correlate with splice 
signatures and favorable outcome in human colorectal 
cancer. Oncotarget. 2016; 7:73800-73816. doi: 10.18632/
oncotarget.12070.
48. Brancaccio M, Rocca S, Secli L, Busso E, Fusella F The 
double face of Morgana in tumorigenesis. Oncotarget. 2015; 
6: 42603-42612. doi: 10.18632/oncotarget.6058.
49. Ropiquet F, Huguenin S, Villette JM, Ronfle V, Le Brun 
G, Maitland NJ, Cussenot O, Fiet J, Berthon P FGF7/KGF 
triggers cell transformation and invasion on immortalised 
human prostatic epithelial PNT1A cells. International 
journal of cancer. 1999; 82: 237-243.
50. Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS, 
Wade PA. MTA3, a Mi-2/NuRD complex subunit, regulates 
an invasive growth pathway in breast cancer. Cell. 2003; 
113: 207-219.
51. Liu P, Begley M, Michowski W, Inuzuka H, Ginzberg M, 
Gao D, Tsou P, Gan W, Papa A, Kim BM, Wan L, Singh A, 
Zhai B, et al. Cell-cycle-regulated activation of Akt kinase 
by phosphorylation at its carboxyl terminus. Nature. 2014; 
508: 541-545.
52. Geninatti-Crich S, Szabo I, Alberti D, Longo D, Aime S 
MRI of cells and mice at 1 and 7 Tesla with Gd-targeting 
agents: when the low field is better! Contrast Media Mol 
Imaging. 2011; 6: 421-425.
